Outcomes in COVID-19 molnupiravir studies
Outcomes in molnupiravir studies.
Potential risks of the mechanism of action include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity [Hadj Hassine , Swanstrom , Waters ] . See
[twitter.com ] for analysis of a variant potentially created by molnupiravir. There is substantial publication bias. Two trials (CTRI/2021/05/033864 and CTRI/2021/08/0354242) reported no significant efficacy, however the results have not been published. Multiple trials have not reported results and did not respond to requests
[Lawrence ] .
0
0.5
1
1.5+
All studies 20% 24
67,989
Improvement, Studies, Patients Relative Risk Mortality 26% 11
57,313
Ventilation 48% 4
5,222
ICU admission 24% 2
42
Hospitalization 7% 14
53,437
Progression 37% 4
9,996
Recovery 19% 7
25,669
Viral clearance 34% 9
7,455
RCTs 42% 12
30,633
RCT mortality 52% 4
26,901
Peer-reviewed 20% 17
22,564
Early 24% 21
67,698
Late -8% 3
291
Molnupiravir for COVID-19 c19 early.org/m Dec 2022Favors molnupiravir Favors control after exclusions
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Fischer (RCT) 77%
0.23 [0.01-5.69]
death
0/140
1/62
Improvement, RR [CI] Treatment Control Hetero (RCT) 70%
0.30 [0.13-0.70]
hosp.
7/371
23/370
Optimus (RCT) 58%
0.42 [0.31-0.58]
viral+
38/175
93/180
Khoo (RCT) -33%
1.33 [0.55-3.26]
no recov.
8/12
3/6
Jayk Bernal (RCT) 89%
0.11 [0.01-0.86]
death
1/709
9/699
Tippabhotla (RCT) 46%
0.54 [0.22-1.34]
hosp.
7/610
13/610
Wong (PSM) 52%
0.48 [0.40-0.59]
death
1,856 (n)
1,856 (n)
Yip (PSW) -12%
1.12 [0.68-1.82]
death/ICU
Flisiak 39%
0.61 [0.38-0.97]
death
20/203
63/387
Khoo (DB RCT) 67%
0.33 [0.01-8.08]
oxygen
0/90
1/90
Kneidinger -15%
1.15 [0.56-2.37]
severe case
8/46
26/172
Najjar-Deb.. (PSM) 19%
0.81 [0.46-1.43]
death
22/2,661
27/2,661
Arbel 65+ 74%
0.26 [0.10-0.73]
death
4/845
137/12,724
Arbel 40-64 -1182%
12.82 [3.41-48.2]
death
4/224
7/6,075
Suzuki (PSM) -100%
2.00 [0.34-11.9]
death
2/230
3/690
Brown -101%
2.01 [0.43-9.38]
hosp.
8/442
2/222
Butler (RCT) 60%
0.40 [0.08-2.06]
death
2/12,516
5/12,484
Wong (PSM) 24%
0.76 [0.61-0.95]
death
Liu -162%
2.62 [0.11-60.6]
ICU
1/26
0/16
Sinha (RCT) 65%
0.35 [0.16-0.73]
hosp.
9/608
26/610
Zheng -100%
2.00 [1.23-3.23]
death/hosp.
61/2,689
34/3,331
OT​1 ​
Tau​2 ​ = 0.28, I​2 ​ = 80.7%, p = 0.072
Early treatment 24%
0.76 [0.56-1.03]
202/24,453
473/43,245
24% improvement 033864 (RCT) 0%
1.00 [0.50-2.00]
improv.
n/a
n/a
FUTILITY, PENDING​2 ​
Improvement, RR [CI] Treatment Control 035424 (RCT) 0%
1.00 [0.50-2.00]
improv.
n/a
n/a
FUTILITY, PENDING​2 ​
Arribas (DB RCT) -282%
3.82 [0.50-29.1]
death
11/216
1/75
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.77
Late treatment -8%
1.08 [0.67-1.73]
11/216
1/75
-8% improvement All studies 20%
0.80 [0.60-1.06]
213/24,669
474/43,320
20% improvement 24 molnupiravir COVID-19 studies c19 early.org/m Dec 2022Tau​2 ​ = 0.27, I​2 ​ = 78.8%, p = 0.12
Effect extraction pre-specified
​1 ​ OT: comparison with other treatment ​2 ​ FUTILITY: terminated for futility, results pending Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Fischer (RCT) 77%
0.23 [0.01-5.69]
death
0/140
1/62
Improvement, RR [CI] Treatment Control Hetero (RCT) 70%
0.30 [0.13-0.70]
hosp.
7/371
23/370
Optimus (RCT) 58%
0.42 [0.31-0.58]
viral+
38/175
93/180
Khoo (RCT) -33%
1.33 [0.55-3.26]
no recov.
8/12
3/6
Jayk Bernal (RCT) 89%
0.11 [0.01-0.86]
death
1/709
9/699
Tippabhotla (RCT) 46%
0.54 [0.22-1.34]
hosp.
7/610
13/610
Wong (PSM) 52%
0.48 [0.40-0.59]
death
1,856 (n)
1,856 (n)
Yip (PSW) -12%
1.12 [0.68-1.82]
death/ICU
Flisiak 39%
0.61 [0.38-0.97]
death
20/203
63/387
Khoo (DB RCT) 67%
0.33 [0.01-8.08]
oxygen
0/90
1/90
Kneidinger -15%
1.15 [0.56-2.37]
severe case
8/46
26/172
Najjar-Deb.. (PSM) 19%
0.81 [0.46-1.43]
death
22/2,661
27/2,661
Arbel 65+ 74%
0.26 [0.10-0.73]
death
4/845
137/12,724
Arbel 40-64 -1182%
12.82 [3.41-48.2]
death
4/224
7/6,075
Suzuki (PSM) -100%
2.00 [0.34-11.9]
death
2/230
3/690
Butler (RCT) 60%
0.40 [0.08-2.06]
death
2/12,516
5/12,484
Wong (PSM) 24%
0.76 [0.61-0.95]
death
Liu -162%
2.62 [0.11-60.6]
ICU
1/26
0/16
Sinha (RCT) 65%
0.35 [0.16-0.73]
hosp.
9/608
26/610
Zheng -100%
2.00 [1.23-3.23]
death/hosp.
61/2,689
34/3,331
OT​1 ​
Tau​2 ​ = 0.28, I​2 ​ = 81.3%, p = 0.051
Early treatment 27%
0.73 [0.54-1.00]
194/24,011
471/43,023
27% improvement 033864 (RCT) 0%
1.00 [0.50-2.00]
improv.
n/a
n/a
FUTILITY, PENDING​2 ​
Improvement, RR [CI] Treatment Control 035424 (RCT) 0%
1.00 [0.50-2.00]
improv.
n/a
n/a
FUTILITY, PENDING​2 ​
Arribas (DB RCT) -282%
3.82 [0.50-29.1]
death
11/216
1/75
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.77
Late treatment -8%
1.08 [0.67-1.73]
11/216
1/75
-8% improvement All studies 22%
0.78 [0.59-1.04]
205/24,227
472/43,098
22% improvement 23 molnupiravir COVID-19 studies after exclusions c19 early.org/m Dec 2022Tau​2 ​ = 0.27, I​2 ​ = 79.4%, p = 0.088
Effect extraction pre-specified
​1 ​ OT: comparison with other treatment ​2 ​ FUTILITY: terminated for futility, results pending Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Fischer (RCT) 77%
0.23 [0.01-5.69]
0/140
1/62
Improvement, RR [CI] Treatment Control Jayk Bernal (RCT) 89%
0.11 [0.01-0.86]
1/709
9/699
Wong (PSM) 52%
0.48 [0.40-0.59]
1,856 (n)
1,856 (n)
Flisiak 39%
0.61 [0.38-0.97]
20/203
63/387
Najjar-Deb.. (PSM) 19%
0.81 [0.46-1.43]
22/2,661
27/2,661
Arbel 65+ 74%
0.26 [0.10-0.73]
4/845
137/12,724
Arbel 40-64 -1182%
12.82 [3.41-48.2]
4/224
7/6,075
Suzuki (PSM) -100%
2.00 [0.34-11.9]
2/230
3/690
Butler (RCT) 60%
0.40 [0.08-2.06]
2/12,516
5/12,484
Wong (PSM) 24%
0.76 [0.61-0.95]
Tau​2 ​ = 0.23, I​2 ​ = 78.8%, p = 0.097
Early treatment 30%
0.70 [0.46-1.07]
55/19,384
252/37,638
30% improvement Arribas (DB RCT) -282%
3.82 [0.50-29.1]
11/216
1/75
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.2
Late treatment -282%
3.82 [0.50-29.1]
11/216
1/75
-282% improvement All studies 26%
0.74 [0.49-1.13]
66/19,600
253/37,713
26% improvement 11 molnupiravir COVID-19 mortality results c19 early.org/m Dec 2022Tau​2 ​ = 0.24, I​2 ​ = 78.1%, p = 0.17
Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Wong (PSM) 58%
0.42 [0.17-1.01]
1,856 (n)
1,856 (n)
Improvement, RR [CI] Treatment Control Flisiak 5%
0.95 [0.39-2.32]
7/203
14/387
Suzuki (PSM) 57%
0.43 [0.02-10.5]
0/230
1/690
Wong (PSM) 60%
0.40 [0.19-0.84]
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.0072
Early treatment 48%
0.52 [0.32-0.84]
7/2,289
15/2,933
48% improvement All studies 48%
0.52 [0.32-0.84]
7/2,289
15/2,933
48% improvement 4 molnupiravir COVID-19 mechanical ventilation results c19 early.org/m Dec 2022Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.0072
Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Wong (PSM) 26%
0.74 [0.45-1.21]
Improvement, RR [CI] Treatment Control Liu -162%
2.62 [0.11-60.6]
1/26
0/16
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.29
Early treatment 24%
0.76 [0.47-1.25]
1/26
0/16
24% improvement All studies 24%
0.76 [0.47-1.25]
1/26
0/16
24% improvement 2 molnupiravir COVID-19 ICU results c19 early.org/m Dec 2022Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.29
Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Fischer (RCT) -33%
1.33 [0.14-12.5]
hosp.
3/140
1/62
Improvement, RR [CI] Treatment Control Hetero (RCT) 70%
0.30 [0.13-0.70]
hosp.
7/371
23/370
Tippabhotla (RCT) 46%
0.54 [0.22-1.34]
hosp.
7/610
13/610
Wong (PSM) 6%
0.94 [0.89-1.00]
hosp. time
1,856 (n)
1,856 (n)
Yip (PSW) -17%
1.17 [0.99-1.39]
hosp.
Flisiak -1%
1.01 [0.71-1.43]
hosp. time
203 (n)
387 (n)
Khoo (DB RCT) 89%
0.11 [0.01-2.03]
hosp.
0/90
4/90
Arbel 65+ 45%
0.55 [0.34-0.88]
hosp.
18/845
513/12,724
Arbel 40-64 -80%
1.80 [0.86-3.77]
hosp.
8/224
97/6,075
Brown -101%
2.01 [0.43-9.38]
hosp.
8/442
2/222
Butler (RCT) -9%
1.09 [0.83-1.45]
hosp.
102/12,516
93/12,484
Wong (PSM) 2%
0.98 [0.89-1.06]
hosp.
Liu 18%
0.82 [0.63-1.06]
hosp. time
26 (n)
16 (n)
Sinha (RCT) 65%
0.35 [0.16-0.73]
hosp.
9/608
26/610
Tau​2 ​ = 0.02, I​2 ​ = 70.3%, p = 0.25
Early treatment 7%
0.93 [0.82-1.05]
162/17,931
772/35,506
7% improvement All studies 7%
0.93 [0.82-1.05]
162/17,931
772/35,506
7% improvement 14 molnupiravir COVID-19 hospitalization results c19 early.org/m Dec 2022Tau​2 ​ = 0.02, I​2 ​ = 70.3%, p = 0.25
Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Fischer (RCT) 77%
0.23 [0.01-5.69]
death
0/140
1/62
Improvement, RR [CI] Treatment Control Hetero (RCT) 70%
0.30 [0.13-0.70]
hosp.
7/371
23/370
Jayk Bernal (RCT) 89%
0.11 [0.01-0.86]
death
1/709
9/699
Tippabhotla (RCT) 46%
0.54 [0.22-1.34]
hosp.
7/610
13/610
Wong (PSM) 52%
0.48 [0.40-0.59]
death
1,856 (n)
1,856 (n)
Yip (PSW) -12%
1.12 [0.68-1.82]
death/ICU
Flisiak 39%
0.61 [0.38-0.97]
death
20/203
63/387
Khoo (DB RCT) 67%
0.33 [0.01-8.08]
oxygen
0/90
1/90
Kneidinger -15%
1.15 [0.56-2.37]
severe case
8/46
26/172
Najjar-Deb.. (PSM) 19%
0.81 [0.46-1.43]
death
22/2,661
27/2,661
Arbel 65+ 74%
0.26 [0.10-0.73]
death
4/845
137/12,724
Arbel 40-64 -1182%
12.82 [3.41-48.2]
death
4/224
7/6,075
Suzuki (PSM) -100%
2.00 [0.34-11.9]
death
2/230
3/690
Brown -101%
2.01 [0.43-9.38]
hosp.
8/442
2/222
Butler (RCT) 60%
0.40 [0.08-2.06]
death
2/12,516
5/12,484
Wong (PSM) 24%
0.76 [0.61-0.95]
death
Liu -162%
2.62 [0.11-60.6]
ICU
1/26
0/16
Sinha (RCT) 65%
0.35 [0.16-0.73]
hosp.
9/608
26/610
Zheng -100%
2.00 [1.23-3.23]
death/hosp.
61/2,689
34/3,331
OT​1 ​
Tau​2 ​ = 0.30, I​2 ​ = 80.4%, p = 0.13
Early treatment 23%
0.77 [0.55-1.08]
156/24,266
377/43,059
23% improvement Arribas (DB RCT) -282%
3.82 [0.50-29.1]
death
11/216
1/75
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.2
Late treatment -282%
3.82 [0.50-29.1]
11/216
1/75
-282% improvement All studies 20%
0.80 [0.57-1.11]
167/24,482
378/43,134
20% improvement 20 molnupiravir COVID-19 serious outcomes c19 early.org/m Dec 2022Tau​2 ​ = 0.30, I​2 ​ = 79.8%, p = 0.18
Effect extraction pre-specified (most serious outcome) ​1 ​ OT: comparison with other treatment Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hetero (RCT) 33%
0.67 [0.54-0.82]
recov. time
371 (n)
370 (n)
Improvement, RR [CI] Treatment Control Khoo (RCT) -33%
1.33 [0.55-3.26]
no recov.
8/12
3/6
Khoo (DB RCT) -12%
1.12 [0.71-1.79]
no recov.
27/90
24/90
Butler (RCT) 22%
0.78 [0.76-0.81]
no recov.
3,874/12,432
4,847/12,151
Tau​2 ​ = 0.01, I​2 ​ = 50.6%, p = 0.0062
Early treatment 21%
0.79 [0.66-0.93]
3,909/12,905
4,874/12,617
21% improvement 033864 (RCT) 0%
1.00 [0.50-2.00]
improv.
n/a
n/a
FUTILITY, PENDING​1 ​
Improvement, RR [CI] Treatment Control 035424 (RCT) 0%
1.00 [0.50-2.00]
improv.
n/a
n/a
FUTILITY, PENDING​1 ​
Arribas (DB RCT) 1%
0.99 [0.68-1.45]
no recov.
72 (n)
75 (n)
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.97
Late treatment 1%
0.99 [0.74-1.34]
0/72
0/75
1% improvement All studies 19%
0.81 [0.71-0.92]
3,909/12,977
4,874/12,692
19% improvement 7 molnupiravir COVID-19 recovery results c19 early.org/m Dec 2022Tau​2 ​ = 0.01, I​2 ​ = 29.9%, p = 0.0018
​1 ​ FUTILITY: terminated for futility, results pending Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Fischer (RCT) 49%
0.51 [0.22-1.18]
viral+
10/118
9/54
Improvement, RR [CI] Treatment Control Optimus (RCT) 58%
0.42 [0.31-0.58]
viral+
38/175
93/180
Tippabhotla (RCT) 59%
0.41 [0.29-0.57]
viral+
42/610
103/610
Wong (PSM) 28%
0.72 [0.61-0.87]
viral+
1,856 (n)
1,856 (n)
Khoo (DB RCT) 23%
0.77 [0.58-1.09]
viral+
90 (n)
90 (n)
Butler (RCT) -13%
1.13 [1.03-1.23]
viral load
203 (n)
241 (n)
Liu 21%
0.79 [0.59-1.05]
viral time
26 (n)
16 (n)
Sinha (RCT) 48%
0.52 [0.42-0.63]
viral load
608 (n)
610 (n)
Tau​2 ​ = 0.17, I​2 ​ = 93.5%, p = 0.0046
Early treatment 36%
0.64 [0.47-0.87]
90/3,686
205/3,657
36% improvement Arribas (DB RCT) 12%
0.88 [0.62-1.25]
viral+
26/52
34/60
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.49
Late treatment 12%
0.88 [0.62-1.25]
26/52
34/60
12% improvement All studies 34%
0.66 [0.50-0.88]
116/3,738
239/3,717
34% improvement 9 molnupiravir COVID-19 viral clearance results c19 early.org/m Dec 2022Tau​2 ​ = 0.16, I​2 ​ = 92.6%, p = 0.0043
Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Fischer (RCT) 77%
0.23 [0.01-5.69]
death
0/140
1/62
Improvement, RR [CI] Treatment Control Hetero (RCT) 70%
0.30 [0.13-0.70]
hosp.
7/371
23/370
Optimus (RCT) 58%
0.42 [0.31-0.58]
viral+
38/175
93/180
Khoo (RCT) -33%
1.33 [0.55-3.26]
no recov.
8/12
3/6
Jayk Bernal (RCT) 89%
0.11 [0.01-0.86]
death
1/709
9/699
Tippabhotla (RCT) 46%
0.54 [0.22-1.34]
hosp.
7/610
13/610
Khoo (DB RCT) 67%
0.33 [0.01-8.08]
oxygen
0/90
1/90
Butler (RCT) 60%
0.40 [0.08-2.06]
death
2/12,516
5/12,484
Sinha (RCT) 65%
0.35 [0.16-0.73]
hosp.
9/608
26/610
Tau​2 ​ = 0.03, I​2 ​ = 13.4%, p < 0.0001
Early treatment 56%
0.44 [0.32-0.60]
72/15,231
174/15,111
56% improvement 033864 (RCT) 0%
1.00 [0.50-2.00]
improv.
n/a
n/a
FUTILITY, PENDING​1 ​
Improvement, RR [CI] Treatment Control 035424 (RCT) 0%
1.00 [0.50-2.00]
improv.
n/a
n/a
FUTILITY, PENDING​1 ​
Arribas (DB RCT) -282%
3.82 [0.50-29.1]
death
11/216
1/75
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.77
Late treatment -8%
1.08 [0.67-1.73]
11/216
1/75
-8% improvement All studies 42%
0.58 [0.39-0.85]
83/15,447
175/15,186
42% improvement 12 molnupiravir COVID-19 Randomized Controlled Trials c19 early.org/m Dec 2022Tau​2 ​ = 0.19, I​2 ​ = 49.7%, p = 0.0056
Effect extraction pre-specified
​1 ​ FUTILITY: terminated for futility, results pending Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Fischer (RCT) 77%
0.23 [0.01-5.69]
0/140
1/62
Improvement, RR [CI] Treatment Control Jayk Bernal (RCT) 89%
0.11 [0.01-0.86]
1/709
9/699
Butler (RCT) 60%
0.40 [0.08-2.06]
2/12,516
5/12,484
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.019
Early treatment 76%
0.24 [0.07-0.79]
3/13,365
15/13,245
76% improvement Arribas (DB RCT) -282%
3.82 [0.50-29.1]
11/216
1/75
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.2
Late treatment -282%
3.82 [0.50-29.1]
11/216
1/75
-282% improvement All studies 52%
0.48 [0.10-2.22]
14/13,581
16/13,320
52% improvement 4 molnupiravir COVID-19 RCT mortality results c19 early.org/m Dec 2022Tau​2 ​ = 1.25, I​2 ​ = 51.8%, p = 0.35
Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hetero (RCT) 70%
0.30 [0.13-0.70]
hosp.
7/371
23/370
Improvement, RR [CI] Treatment Control Khoo (RCT) -33%
1.33 [0.55-3.26]
no recov.
8/12
3/6
Jayk Bernal (RCT) 89%
0.11 [0.01-0.86]
death
1/709
9/699
Tippabhotla (RCT) 46%
0.54 [0.22-1.34]
hosp.
7/610
13/610
Wong (PSM) 52%
0.48 [0.40-0.59]
death
1,856 (n)
1,856 (n)
Yip (PSW) -12%
1.12 [0.68-1.82]
death/ICU
Flisiak 39%
0.61 [0.38-0.97]
death
20/203
63/387
Khoo (DB RCT) 67%
0.33 [0.01-8.08]
oxygen
0/90
1/90
Kneidinger -15%
1.15 [0.56-2.37]
severe case
8/46
26/172
Najjar-Deb.. (PSM) 19%
0.81 [0.46-1.43]
death
22/2,661
27/2,661
Suzuki (PSM) -100%
2.00 [0.34-11.9]
death
2/230
3/690
Brown -101%
2.01 [0.43-9.38]
hosp.
8/442
2/222
Wong (PSM) 24%
0.76 [0.61-0.95]
death
Liu -162%
2.62 [0.11-60.6]
ICU
1/26
0/16
Sinha (RCT) 65%
0.35 [0.16-0.73]
hosp.
9/608
26/610
Zheng -100%
2.00 [1.23-3.23]
death/hosp.
61/2,689
34/3,331
OT​1 ​
Tau​2 ​ = 0.21, I​2 ​ = 77.7%, p = 0.1
Early treatment 23%
0.77 [0.57-1.05]
154/10,553
230/11,720
23% improvement Arribas (DB RCT) -282%
3.82 [0.50-29.1]
death
11/216
1/75
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.2
Late treatment -282%
3.82 [0.50-29.1]
11/216
1/75
-282% improvement All studies 20%
0.80 [0.59-1.08]
165/10,769
231/11,795
20% improvement 17 molnupiravir COVID-19 peer reviewed studies c19 early.org/m Dec 2022Tau​2 ​ = 0.22, I​2 ​ = 77.1%, p = 0.15
Effect extraction pre-specified (most serious outcome) ​1 ​ OT: comparison with other treatment Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Fischer (RCT) 77%
0.23 [0.01-5.69]
death
0/140
1/62
Improvement, RR [CI] Treatment Control Fischer (RCT) 65%
0.35 [0.01-8.33]
death
0/55
1/62
Fischer (RCT) 67%
0.33 [0.01-8.03]
death
0/62
1/62
Fischer (RCT) 58%
0.42 [0.02-10.0]
death
0/23
1/62
Fischer (RCT) -33%
1.33 [0.14-12.5]
hosp.
3/140
1/62
Fischer (RCT) -13%
1.13 [0.07-17.6]
hosp.
1/55
1/62
Fischer (RCT) -100%
2.00 [0.19-21.5]
hosp.
2/62
1/62
Fischer (RCT) 58%
0.42 [0.02-10.0]
hosp.
0/23
1/62
Fischer (RCT) 49%
0.51 [0.22-1.18]
viral+
10/118
9/54
Fischer (RCT) 89%
0.11 [0.01-0.86]
viral+
1/53
9/54
Fischer (RCT) 30%
0.70 [0.25-1.93]
viral+
5/43
9/54
Fischer (RCT) -9%
1.09 [0.37-3.18]
viral+
4/22
9/54
Fischer (RCT) 92%
0.08 [0.01-0.62]
viral+
1/117
6/54
Fischer (RCT) 92%
0.08 [0.00-1.34]
viral+
0/53
6/54
Fischer (RCT) 91%
0.09 [0.00-1.48]
viral+
0/42
6/54
Fischer (RCT) 59%
0.41 [0.05-3.20]
viral+
1/22
6/54
Fischer (RCT) 30%
0.70 [0.37-1.36]
viral+
19/137
12/61
Fischer (RCT) 62%
0.38 [0.13-1.12]
viral+
4/53
12/61
Fischer (RCT) -8%
1.08 [0.54-2.18]
viral+
13/61
12/61
Fischer (RCT) 56%
0.44 [0.11-1.83]
viral+
2/23
12/61
Hetero (RCT) 70%
0.30 [0.13-0.70]
hosp.
7/371
23/370
Hetero (RCT) 33%
0.67 [0.54-0.82]
recov. time
371 (n)
370 (n)
Optimus (RCT) 58%
0.42 [0.31-0.58]
viral+
38/175
93/180
Khoo (RCT) -33%
1.33 [0.55-3.26]
no recov.
8/12
3/6
Khoo (RCT) -100%
2.00 [0.28-14.2]
no recov.
4/12
1/6
Khoo (RCT) -100%
2.00 [0.90-4.43]
no recov.
4/4
3/6
Khoo (RCT) 0%
1.00 [0.28-3.54]
no recov.
2/4
3/6
Khoo (RCT) 0%
1.00 [0.28-3.54]
no recov.
2/4
3/6
Khoo (RCT) -50%
1.50 [0.13-17.7]
no recov.
1/4
1/6
Khoo (RCT) -200%
3.00 [0.39-23.1]
no recov.
2/4
1/6
Khoo (RCT) -50%
1.50 [0.13-17.7]
no recov.
1/4
1/6
Jayk Bernal (RCT) 89%
0.11 [0.01-0.86]
death
1/709
9/699
